Combined scleral buckle and BGI is effective

Article

Combined scleral buckle and Baerveldt glaucoma implantation (BGI) is effective for managing coexisting glaucoma and retinal detachment.

Combined scleral buckle and Baerveldt glaucoma implantation (BGI) is effective for managing coexisting glaucoma and retinal detachment, while minimizing surgical risk, states a journal paper.

Professor V.C. Lima et al., Department of Ophthalmology and Einhorn Clinical Research Center, The New York Eye and Ear Infirmary, New York, USA, included 30 eyes of 30 patients in a retrospective, consecutive, noncomparative, interventional case series.

All patients underwent simultaneous scleral and BGI surgery and were separated into a staged BGI group of 21 patients and a non-staged BGI group consisting of 9 patients. Successful IOP control was identified as 6 mmHg ≤ IOP ≤ 18 mmHg.

Mean best-corrected visual acuity improved from 2.0 preoperatively to 1.7 postoperatively. In the staged group 62% required second-stage tube insertion postoperatively. Mean IOP was reduced from 31.1±10.8 to 12.7±6.0 mmHg, mean number of glaucoma medications was lowered from 2.9±1.4 to 1.2±1.3.

Combined scleral buckle and BGI is a successful management technique for coexisting glaucoma and retinal detachment and greatly reduces surgical risk.

Please visit the Journal of Glaucoma for more information.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
© 2025 MJH Life Sciences

All rights reserved.